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Abstract 
Tumor initiation and progression are the outcomes of a stepwise accumulation of genetic 
alterations. Among these, gene amplification and aberrant expression of oncogenic proteins, and 
deletion or inactivation of tumor suppressor genes, represent hallmark steps. Mounting evidence 
collected over the last few years identifies different populations of non-coding RNAs as major 
players in tumor suppression in almost all cancer types. Elucidating the diverse molecular 
mechanisms underlying the roles of non-coding RNAs in tumor progression might provide 
illuminating insights, potentially able to assist improved diagnosis, better staging and effective 
treatments of human cancers. Here we focus on several groups of tumor suppressor microRNAs, 
whose downregulation exerts a profound oncologic impact and might be harnessed for the benefit 
of cancer patients. 
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Introduction 
In most epithelial tissues, cancer develops through separate and interrelated steps of clonal 
expansion, genetic diversification, and clonal selection. During cancer development, cancer cells 
acquire diverse biological capabilities that are conferred by the numerous genetic and epigenetic 
modifications [1]. In recent years, different high-throughput platforms have been used for the 
genomic, transcriptomic, proteomic, and epigenomic analyses to search for new biomarkers 
involved in cancer and to bring new insights into the several aspects of cancer pathophysiology  [1]. 
In addition to the classical transcriptional cell regulators involved in cancer development, a class of 
noncoding RNAs, termed microRNAs (miRNAs) has emerged as critical regulators of gene 
expression acting predominantly at the post-transcriptional level. MiRNAs were first identified 
through their ability to regulate developmental processes, such as developmental timing and cell 
fate transitions [2]. Subsequently, miRNAs have been studied in relation to cancer development.  A 
large number of miRNAs that map to specific regions of the human genome have been shown to be 
frequently deleted or amplified in cancer [3].  Several lines of evidence indicate that miRNAs might 
be differentially expressed in cancer cells, in which they forme unique expression patterns or 
signature [4].  Sevignani and colleagues reported a significant association between the 
chromosomal location of miRNAs and those of mouse susceptibility loci that influence the 
development of solid tumors [5]. Dysregulation of miRNAs in cancer can occur through both 
epigenetic changes, including aberrant DNA methylation and histone modification [6], and genetic 
alterations.  These two biological mechanisms can affect the production of the primary RNAs, their 
processing to the mature miRNA forms, and/or interactions with mRNA targets [7]. 
More recent studies indicate that mutations affecting proteins involved in the processing and 
maturation of miRNA, such as TARBP2, DICER1 and XPO5, can also lead to overall reductions in 
miRNA expression [8-10]. Consistent with these observations, miRNAs are thought to act mainly 
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as tumor suppressor genes, and their dysregulation is currently recognized as a common feature of 
human cancers. Later on, additional data indicated that the expression of miRNAs is mainly 
downregulated in tumor tissues, as compared to corresponding healthy tissues, which supported the 
role of miRNAs as primarily tumor suppressors [4, 8, 9, 11, 12]. In the same vein, there is evidence 
that an extensive down-regulation of miRNAs is one of the first outcomes of the stimulation of 
signaling cascades downstream to specific growth factor receptors implicated in a number of human 
cancers, including breast cancer [13]. For example, EGF signaling rapidly and simultaneously 
induces an extensive down-regulation of multiple microRNAs, reflecting coordinated regulation at 
the level of microRNA synthesis, processing or degradation [13].  
MiRNAs are also deregulated upon exposure to both metabolic cancer risk factors and 
exposures to carcinogenic substances [14, 15]. Thus, miRNAs may represent at the same time both 
predictors and players of cancer development.   A number of life-style factors (e.g., diet rich in fats 
and refined carbohydrates) and pathological conditions (e.g., obesity), often related to inflammation 
and cancer, result in deregulation of specific microRNAs [16-19].  There is evidence of an altered 
expression of miRNAs in relation to the exposure to well-known carcinogenic substances such as 
asbestos, formaldehyde and cigarette smoke in lung and hepatic tissue [20, 21]. In regard to this 
evidence, one study examined the expression of 484 miRNAs in the lungs of rats exposed to 
environmental cigarette smoke for 4 weeks. It was found that 126 miRNAs were down-regulated at 
least 2-fold and 24 miRNAs were downregulated more than 3-fold [22].   
In this review, we highlight the contribution of miRNA modulation, in particular prevalent 
downregulation of specific miRNAs, to cancer development.  Because many downregulated 
miRNAs function as tumor suppressors, better understanding  of the biological mechanisms 
underlying their modulation will enable new strategies for early detection, prevention and therapy 
of cancer.   
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MicroRNA-10b3p: the early arm of the microRNA-10b locus 
The so called microRNA-10b locus is located on chromosome 2, within the cluster of the HOXD 
genes, in an intergenic region between HOXD4 and HOXD8 [23]. Processing by Drosha and Dicer, 
transforms the RNA product of the microRNA-10b locus into a 22-nucleotide RNA duplex that 
contains two distinct 5’ phosphorylated strands with 3’ overhangs (Figure 1). The functional strand 
of the duplex, referred to as the guide strand, is microRNA-10b5p while the other, passenger strand 
generates microRNA-10b3p. MicroRNA-10b5p was originally identified as a molecules down-
regulated in primary breast tumors, compared to normal breast tissues [24]. Similarly, down-
regulation of microRNA 10b5p by promoter hypermethylation has been reported in gastric tumors 
[25]. The Weinberg’s group has later reported that microRNA-10b5p acts as a metastasis-
supporting microRNA, due to its ability to favor migration and invasion of breast cancer cells [26, 
27]. In line with this, microRNA-10b5p targets the HOXD10 gene, a repressor of several 
modulators of cell migration [26]. The expression of microRNA-10b5p is tightly controlled by the 
transcription factor Twist, a well-established regulator of epithelial-to mesenchymal transition 
(EMT). Increased expression of microRNA-10b5p was detected in the vasculature of breast IDC 
(invasive ductal carcinoma) grade III tumors compared to lower expression in DCIS (ductal 
carcinoma in situ) [28]. The pleiotropic activity of microRNA-10b5p could also rely on its ability to 
target the expression of diverse tumor suppressors including TP53, HODX10, PAX6, NOTCH1 and 
FOXO3 (see Table 1) [29] .  
Biagioni et al. originally reported that the expression of microRNA-10b3p was down-
regulated in breast tumors, relative to matched peritumoral tissues [12]. This down-regulation 
occurred, at least in part, through the methylation of CpG islands located within the regulatory 
regions of the microRNA-10b locus [12]. Ectopic expression of microRNA-10b3p inhibited 
proliferation of breast cancer cell lines and reduced the size of xenografted breast tumors [12]. 
Three pivotal proteins involved in the control of cell proliferation, namely BUB1, PLK1, and 
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CCNA2, were shown to serve as targets of microRNA-10b3p. Accordingly, intratumoral injection 
of a mimic of microRNA-10b3p reduced the expression of BUB1, PLK1 and CCNA2 proteins [12]. 
The prognostic role of microRNA-10b3p and of its target was evaluated in the MEATBRIC dataset. 
This analysis included 1,286 breast cancers from 5 different subtypes: HER2+ (127 patients), basal-
like (209 patients), luminal A (479 patients), luminal B (312 patients), and normal-like (151 
patients) and for which both mRNA and microRNA data were availble [12]. mRNAs and miRNAs 
were measured for each tumoral and normal samples of the METABRIC dataset. Kaplan-Meyer 
analysis revealed a significant association between low expression levels of miR-10b3p and poor 
disease-specific survival [12]. This association was not evidenced for the augmented expression of 
microRNA-10b5p. The combined application of COSMIC algorithm [30] and miRanda predictions 
uncovered 15 target mRNAs of microRNA-10b3p [12]. Among those targets there, BUB1, PLK1 
and CCNA2 were confirmed, and additional cell cycle related targets were also identified. Increased 
expression of BUB1, PLK1 and CCNA2 was associated with poor survival (Table 1) [12].  
These findings have several implications to the roles played by microRNA-10b in breast 
tumorigenesis. Presumably, the expression of microRNA-10b3p is altered in the early stages of 
mammary cell transformation. This could lead to aberrant cell proliferation, mediated by increased 
expression of the cell cycle related targets of microRNA-10b3p. In line with early alterations, 
down-regulation of microRNA-10b3p expression appears to occur independently from the subtype 
of breast cancer, suggesting that it might represent an event preceding specification of breast cancer 
subtypes. Interestingly, the regulation of the expression of the two strands derived from the 
microRNA-10b locus is controlled by the combination of epigenetic and transcriptional events. 
While down-regulation of microRNA10b-3p occurs through methylation of CpG islands, the 
transcription factor TWIST up-regulates the expression of microRNA-10b5p [26]. This might 
underlie mechanistically the dual and opposite roles of the microRNA-10b locus. Early in breast 
tumorigenesis microRNA-10b3p down-regulation leads to aberrant cell proliferation, while 
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TWIST-mediated transcriptional induction of microRNA-10b5p contributes, as a late step, to shape 
a metastatic phenotype.  
Unlike down-regulation of microRNA-10b3p, which occurs independently from the breast 
cancer subtype, upregulation of microRNA-10b5p might be specifically selected in highly 
metastatic breast tumors. Thus, waves of microRNA-10b3p and 5p targets might tune the pro-
proliferative and pro-metastatic activities of the aberrantly activated microRNA-10b locus. 
Intriguingly, microRNA-10b3p (previously named microRNA-10b*) could represent a prototype of 
microRNAs derived from passenger strands, which target specific mRNAs and exert biological 
activities as efficiently as those originated from guide strands. While the role of microRNA-10b5p 
is relatively well documented in different human cancers, that of microRNA-10b3p is poorly 
investigated. This also indicates that the microRNA-10b locus, via downregulation of the 3p strand 
or up-regulation of 5p plays a pivotal role in breast cancer establishment or dissemination. Once, 
the molecular events responsible for aberrant activation of the microRNA-10b locus in tumors will 
be fully understood, they might hold promise for novel therapeutic strategies. This might turn true 
also for passenger derived tumor suppressor microRNAs. 
 
Let-7c acts as a tumor suppressor microRNA 
The let-7 family is one of the most ancient and conserved groups of microRNAs, showing high 
conservation across species from Caenorhabditis elegans to mammals [31]. In humans, the let-7 
family is comprised of ten members (let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-
98 and miR202), which differ in their nucleotide sequences. Some of the isoforms appear in 
multiple copies in the genome, hence a number is added as a suffix to their name (e.g., let-7a-1, let-
7a-2 and let-7a-3) (reviewed in [32]). Interestingly, many of the let-7 miRNAs are located in fragile 
sites and specific genomic regions that relate to cancer [3]. Thus, for example, in the human 
genome, the cluster let-7a-1/let-7f-1/let-7d is included in a frequently deleted region of 
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chromosome 9 (region B at 9q22.3). In breast carcinomas, a region of LOH (loss of heterozygosity) 
at 11q23 was shown to harbour the cluster miR-125b1/let-7a-2/miR-100, and the cluster miR-
99a/let-7c/miR-125b-2 resides at 21p11.1, a region of frequent HD (homozygous deletions) in lung 
cancers. Furthermore, let-7a-1, let-7f-1, let-7d and miR-202 are located close to class II homeotic 
genes in the human HOX gene clusters [3]. 
The let-7 family plays crucial roles in cellular differentiation and in development, and it 
displays specific temporal and spatial expression patterns during development of several species 
[31, 33]. For example, in mammals, the level of let-7 increases during embryogenesis and during 
brain development [34]. In concordance with developmental roles for the let-7 family, members of 
this family are also involved in cancer, and as discussed below, many of them act as tumor 
suppressor miRNAs. Downregulation of most let-7 family miRNAs was demonstrated in several 
types of human cancer, including lung, head and neck squamous cell carcinoma, breast, melanoma, 
ovarian and prostate cancers. Interestingly, silencing all let-7 family members in ovarian cancer cell 
lines increased cell survival, invasion and adhesion [35]. The targets of let-7 are also conserved 
from worms to humans, and they include known oncogenic transcripts, such as MYC and RAS 
[36]. Interestingly, the viral homolog of KRAS contains a single nucleotide polymorphism (SNP) in 
its potential let-7 binding site, which increases the risk for lung, oral and colorectal cancers [37-39]. 
Another cancer related target of the let-7 family is the high-mobility group AT-hook 2 (HMGA2) 
oncoprotein, a chromatin-associated non-histone protein that affects transcription by modulating 
chromatin’s architecture [40]. 
Let-7c, a member of the let-7 family, functions as a tumor suppressor in several types of 
cancer (Figure 2). It targets various oncogenes and cancer related genes, such as: N-RAS, C-MYC, 
HMGA2, MMP11, PBX2, PBX3, TRIB2, ITGB3, TGFBR1, BCL-XL and MAP4K3 [36, 37, 40-
42] (see Table 2). In support of a role for let-7c as a tumor suppressor, its reduced expression was 
demonstrated in tumors and cultured cells from prostate, lung, colorectal and hepatocellular tumors 
[41, 43-46]. Additionally, downregulation of let-7c was associated with poor prognosis in colorectal 
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cancer, where let-7c expression was significantly lower in patients presenting lymph node 
involvement or distant metastases, compared to patients without any detectable metastasis [43]. In 
non-small cell lung carcinoma (NSCLC), low expression of let-7c was associated with poor patient 
survival, as well as with tumor spread, venous invasion and advanced disease stages [46]. 
Interestingly, let-7c is encoded by chromosomal locus 21q21, which shows loss of heterozygosity in 
lung cancer [47].  
The maturation process of miRNAs of the let-7 family, including that of let-7c, is regulated 
by the RNA-binding proteins called Lin28 and Lin28B, which employ several different regulatory 
mechanisms [48]. Lin28 is expressed in the cytoplasm and blocks processing of let-7 by Dicer 
through direct binding to the terminal loop of pre-let-7 and by recruiting the terminal uridyl 
transferase (TUTase) Zcchc11/TUT4 to catalyze the oligouridine tail, thus marking pre-let-7 for 
degradation [49, 50]. Lin28B is found mainly in the nucleolus and upon binding to pri-let-7 it 
blocks the activity of the microprocessor complex through TUTase-independent mechanism 
[reviewed by [51]]. Interestingly, miRNAs of the let-7 family have been suggested to reciprocally 
downregulate the expression of Lin28 and Lin28B and thus increase the levels of mature let-7 
family miRNAs [52, 53]. Let-7c’s expression levels can also be regulated by the peroxisome 
proliferator-activated receptor α (PPARα) in hepatocellular carcinoma cells [45]. 
Manipulation of let-7c expression in cancer cell lines further established its role as a tumor 
suppressor. For example, overexpression of let-7c decreased, whereas depletion of let-7c increased 
cell proliferation and clonogenicity of prostate cancer cells in-vitro. Let-7c also exerted an anti-
proliferative effect in-vivo, when tested by intratumoral injection of let-7c, which significantly 
reduced tumor size in xenografts of human prostate cancer cells [44].  According to recent studies, 
let-7c can also function as a metastasis suppressor. In highly metastatic colorectal adenocarcinoma 
cells, ectopic over-expression of let-7c led to reduced migration and invasion in vitro, and almost 
completely inhibited tumor growth and metastasis. When tested in weakly metastatic cells, let-7c 
inhibition resulted in increased cell motility and invasion. These effects of let-7c on motility were 
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likely mediated by targeting of KRAS, MMP11 and PBX3 [43]. Additionally, ectopic let-7c 
expression in chemotherapy-resistant lung adenocarcinoma cells reduced the number of metastatic 
nodules in lung and liver, probably via inactivation of the AKT pathway [37]. 
In addition to the AKT pathway, let-7c controls several other cancer-related signalling 
pathways. Thus, let-7c plays an important role in the regulation of androgen receptor (AR) 
signalling by directly targeting MYC, thereby controlling prostate cancer proliferation. 
Accordingly, the expression of let-7c and AR are negatively correlated in human prostate cancer, 
where AR, MYC and Lin28 expression levels are high while let-7c expression level is low [54]. In 
acute leukaemia, let7-c targets PBX2, a homeodomain protein, which upon aberrant expression 
enhances HoxA9-dependent leukemogenesis, and promotes granulocytic differentiation [41]. Let-7c 
may also suppress cell growth and control cancer pathogenesis by regulating the mitogen-activated 
protein kinase (MAPK) pathway. In lung adenocarcinoma let-7c directly targets TRIB2, which in 
turn activates the downstream components, C/EBP-α and a phosphorylated p38-MAPK [55]. 
Another pathway by which let-7c can regulate the MAPK pathway is through its role in controlling 
NRAS expression [36]. One of the key metastasis-driving processes is EMT [56], which is affected 
by several transcriptional switches, including a let-7c regulated switch. Docetaxel-resistant lung 
adenocarcinoma cells are characterized by fibroblast-like morphology and adhesion, which are 
typical of the mesenchymal phenotype. However, upon expression of the let-7c precursor, these 
cells gained an epithelial phenotype, which might contribute to the restoration of chemo- and radio-
sensitivity. This effect of let-7c is possibly achieved through direct targeting of BCL-XL [37].   
In summary, let-7c plays a crucial role in cancer pathogenesis through targeting key cancer-
related proteins and acting both as a suppressor of both tumor growth and tumor spread. Thus, let-
7c is might be considered an attractive candidate for drug-induced manipulation in cancer therapy.   
!
!
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miR%223!in!cell!differentiation!and!tumor!suppression.!
MiR-223 was initially identified as a miRNA nearly exclusively expressed in bone marrow, such 
that its functional role in the regulation of the cell fate determination of human hematopoietic 
progenitors cells (HPCs) rapidly emerged [57, 58]. Recently, Vian and colleagues evidenced that in 
human CD34+HPCs undergoing unilineage differentiation/maturation, miR-223 is up-regulated 
during granulopoiesis rather than during monocytopoiesis and is maintained at low levels during 
erythropoiesis [59]. Interestingly, miR-223 overexpression in human CD34+HPCs favors 
granulopoiesis and impairs erythroid and monocytic/macrophagic differentiation [59].  
The fine-tuning of miR-223 expression levels during hematopoietic differentiation of HPCs, 
as well as of myeloid cell lines, into erythroid, granulocytic and monocytic/macrophagic lineages is 
the result of the coordinated recruitment and function of lineage-specific transcription factors (TFs) 
on two different regulatory regions of the miR-223 promoter [58, 59]. For example, during 
granulocytic differentiation of human myeloid progenitors, the induction of miR-223 expression is 
transcriptionally regulated by the competitive binding of two TFs, Nuclear Factor I (NFI-A) and 
CCAAT/enhanced-binding protein alpha (C/EBPα), to the proximal miR-223 regulatory region. 
NFI-A maintains miR-223 transcription at low levels, while its replacement by C/EBPα results in 
miR-223 induction and granulocytic differentiation [60]. NFI-A was also identified as a target for 
miR-223 at transcriptional and translational level, thus establishing a feedback regulatory circuitry 
in the control of granulopoiesis [58, 61].  
Interestingly, miR-223 expression is down-regulated in different subtypes of acute myeloid 
leukemia (AML), that represents the clonal expansion of hematopoietic precursors blocked at 
different stages of differentiation [62]. In particular, primary blasts carrying the t(8;21) generating 
AML1/ETO, the most common acute myeloid leukemia-associated fusion protein, present very low 
levels of  miR-223 expression. In these cells the AML1-ETO oncoprotein, which recruits an 
epigenetic silencing complex consisting of HDACs, DNMTs, and methyl-CpG-binding proteins on 
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the AML1 binding site of the miR-223 promoter, links the epigenetic silencing of a microRNA 
locus to the differentiation block of this acute myeloid leukemia subtype [62]. Of note, the enforced 
expression of miR-223 in primary AML blasts and in AML cell lines affects cell cycle progression 
and enhances granulocyte differentiation [58, 59, 62, 63].  
The tumor suppressor function of miR-223 in acute myeloid leukemia is further supported 
by a recent study showing that the induction of miR-223 inhibits the translation of the cell-cycle 
regulator E2F1 and significantly down-regulates the proliferation rate of myeloid progenitors cells 
[63]. Of note, E2F1 transcriptionally represses miR-223 gene in AML cells, suggesting that the 
miR-223 function as a key regulator of myeloid cell proliferation is strictly linked with E2F1 
activity in a mutual negative feedback loop [63]. 
Exosomes or microvesicles are emerging as important mediators of intercellular cross-talk 
for the regulation of a variety of biological functions, as cellular communication, proliferation and 
differentiation [64]. Microvesicle transfer represents a novel mechanism by which infiltrating 
mononuclear phagocytes may contribute to cellular activation, survival, and immune function. 
MiR-223 was evidenced to be the most highly expressed miRNA in the macrophage-derived 
microvesicles that are able to induce cellular differentiation when added to naive monocytes, 
supporting a functional amplification loop to enhance immune function (Figure 3A) [65]. 
In addition to the exosome-mediated transfer of nucleic acids, tissue macrophages were also 
shown to be able to transfer miR-223 to hepato-carcinoma cells (HCCs) in a manner that required 
intercellular contact and gap junction communication (Figure 3B) [66]. Functionally, the transfer of 
miR-223 from macrophages to HuH7 cells resulted in the inhibition of proliferation of these HCCs 
cancer cells, thus highlighting intercellular transfer of miRNA from immune cells as a new possible 
mechanism of defense against neoplastic cell transformation or tumor growth [66]. The transfer of 
miR-223 influences protein expression in HuH7 cells. Specifically, miR-223 decreases the 
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expression of Stathmin-1 (STMN1) and insulin-like growth factor-1 receptor (IGF-1R), which both 
influence cellular proliferation and can support the growth of tumors [67, 68]. 
STMN1 is a key microtubule-regulatory protein that controls microtubule dynamics, cell 
proliferation and, in particular, the S-phase of the cell cycle. High-levels of STMN1 have been 
associated with increased histologic grading, shorter patient survival times, and increased drug 
resistance in different tumors. STMN1 is a protein that is usually present at low levels in healthy 
hepatocytes but is expressed at high levels in hepato-carcinomas [67]. In HCC cell lines, a strong 
inverse relationship between STMN1 mRNA and miR-223 expression was observed and a 
substantial reduction in STMN1 protein was demonstrated upon restoration of miR-223 expression, 
resulting in a consistent inhibitory effect on cell viability [67]. 
In line with these lines of evidence, it was recently reported that modulation of miR-
223/STMN-1 pathway represents another way by which mutant p53 increases cellular resistance to 
chemotherapeutic drugs [69]. The induction of mutant p53R175H in breast and colon cancer cell lines 
decreases miR-223 expression. Mutant p53R175H, together with the transcriptional repressor ZEB-1, 
binds to the miR-223 promoter and decreases miR-223 expression, resulting in an up-regulation of 
STMN-1 and in an increased cellular resistance to chemotherapeutic agents. On the contrary, 
ectopic expression of miR-223 can lower the levels of STMN-1 and sensitize breast and colon 
cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs [69]. 
By targeting IGF-1R and the cyclin-dependent kinase 2 (CDK2), miR-223 functions as a 
potent tumor suppressor also in the Lewis lung carcinoma (LLC) cell line [70]. Ectopic expression 
of miR-223 suppresses proliferation, invasion and tumorigenicity of LLC cells, induces G2/M 
phase arrest and inhibits tumor growth in vivo, providing the basis for novel therapies targeting 
IGF‑1R in the treatment of NSCLC [70]. 
The inhibition of cancer cells proliferation by miR-223 was recently reported also in 
colorectal cancer [71]. The colorectal cancer HCT116 cells express very low levels of endogenous 
miR-223 and the miR-223 overexpression in these cells reduces mRNA and protein expression 
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levels of FOXO1, whose abnormal expression or activation can result in aberrant apoptotic 
pathways, proliferation, and cell cycle regulation. Interestingly, miR-223 overexpression mainly 
increases the unphosphorylated FOXO1 protein, its nuclear localization, as well as cyclin 
D1/p21/p27 at either mRNA or protein accumulation and inhibition of tumor cell proliferation [71].  
Although several experimental evidences support the involvement of miR-223 in cell differentiation 
and tumor suppression, miR-223 was also reported to be up-regulated in some tumors and to 
contribute to leukemogenesis in specific disease subtypes (T-ALL), indicating that the biologic 
effect of miR-223 strongly depends on the cellular context where this miRNA specifically performs 
its function [72, 73]. 
 
miR-145 in tumor suppression  
miR-145 is located at chromosome 5q33.1 and is usually transcribed in a bicistronic primary 
transcript with miR-143 [74]. Of note, miR-145 represents one of the miRNAs that are highly 
expressed in normal tissues but they are down-regulated in several human cancers, including 
colorectal and breast cancer [24, 75]. Although the down-regulation of miR-145 expression in 
human cancer may result from genetic aberrations, as occurs in hematological malignancies 
associated to the 5q- syndrome phenotype [76], a major mechanism for the modulation of miR-145 
expression is represented by transcriptional and post-transcriptional control. Interestingly, 
transcriptional contribution to the regulation of miR-145 expression was reported in breast and in 
colon cancer cell lines where p53, by interacting with a consensus sequence in the miR-145 
promoter, transcriptionally induces miR-145 expression, promoting the post-transcriptional down-
regulation of MYC and consequently the inhibition of tumor cell growth [77]. In line with these 
results, in prostate cancer tissues and cell lines, miR-145 was found to be silenced through the 
methylation of its promoter, and miR-145 silencing was significantly correlated to the status of the 
p53 gene [78]. A recent study also reported that the CCAAT/enhancer binding protein beta 
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(C/EBPβ) is able to counteract the p53-mediated induction of miR-145. In fact, C/EBPβ induces the 
transcriptional down-regulation of miR-145 expression by interacting with a CCAAT binding site 
located in miR-145 promoter; this down-regulation seems to be independent from p53 and involves 
the AKT pathway [79].   
Concerning miR-143/miR-145 processing, it was recently reported that p53 itself may be 
involved in the post-transcriptional maturation of several miRNAs with growth-suppressive 
functions in response to DNA damage, including miR-143/miR-145. In particular, the p53 protein, 
through the association with the DEAD-box RNA helicase p68 (also known as DDX5), interacts 
with the Drosha processing complex thus supporting the processing of primary miRNAs to 
precursor miRNAs.  On the contrary, p53 mutated proteins interfere with the functional assembly 
between the Drosha complex and p68, inducing an attenuation of miRNA processing activity [80].
 Moreover, it was also recently reported that the DEAD-box RNA helicase 6 (DDX6), that is 
highly expressed in most malignant cells, post-transcriptionally down-regulates both miR-143 and 
miR-145 expression. In human gastric cancer cells, DDX6 protein, that is abundantly expressed and 
accumulated in processing bodies (P-bodies) containing many proteins involved in mRNA turnover, 
negatively regulates the RNA stability of the bicistronic primary transcript resulting in the down-
regulation of both miR-143 and miR-145 [81]. Several reports, supporting miR-145’s activity as a 
tumor suppressor in different tumor types, have revealed that the down-regulation of miR-145 
expression is associated to neoplastic cell growth and proliferation, as well as to cancer cell 
migration, invasion and metastasis (Table 4) [82-87]. 
In colon cancer the tumor suppressor function of miR-145 was initially related to the down-
regulation of the insulin receptor substrate-1 (IRS-1). Of note, in human colon cancer cells miR-
145, by targeting the 3’ UTR of IRS-1, dramatically down-regulates IRS-1 protein, thereby 
inducing cell growth arrest [88]. In colon cancer cell lines, YES and STAT1 factors were also 
evidenced as additional miR-145 targets [89]. Interestingly, in colon cancer tissues low miR-145 
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expression levels are inversely correlated to p70S6K1 protein levels. On the contrary, the forced 
expression of miR-145, by targeting p70S6K1, resulted in the down-regulation of two downstream 
molecules of p70S6K1 pathway, the VEGFA and HIF-1α proteins, thus inhibiting tumor growth 
and angiogenesis [90].  
The tumor suppressive function of miR-145 on cancer cell proliferation was also recently 
reported in lung cancer. By targeting the EGFR and nucleoside diphosphate linked moiety X-type 
motif 1 (NUDT1) at both mRNA and protein levels, miR-145 inhibits lung adenocarcinoma cell 
proliferation and lung tumorigenesis [91]. Of note, the prognostic value of miR-145 was originally 
evidenced in lung cancer, where the low expression miR-145 is significantly correlated with a 
worse prognosis and survival of adenocarcinoma patients [92]. 
In breast cancer tissues, miR-145 expression is inversely correlated with the stage of 
malignancy. In particular, miR-145, through the post-transcriptional regulation of N-RAS and 
VEGFA expression, exhibits inhibitory roles in tumor angiogenesis, invasion and tumor growth 
[93]. Accordingly, in the human breast cancer cell line MCF-7, miR-145 induction was shown to 
promote the inhibition of cell growth and the induction of apoptosis by targeting the Rho-effector 
rhotekin (RTKN) [94]. A death-promoting loop between miR-145 and TP53 was also identified in 
MCF7 breast cancer cells expressing wild-type TP53. miR-145 indeed activates the p53 pathway, 
resulting in the promotion of apoptosis, and sustaining in turn a further induction of miR-145 
expression. In the same context, miR-145 may also down-regulate estrogen receptor-alpha (ER-a) 
protein expression, whereby a miR-145 re-expression therapy was proposed, at least for the 
subgroup of patients with ER-a-positive and/or TP53 wild-type tumors [95]. Interestingly, the re-
expression of miR-143/miR-145 was also shown to suppress the cellular growth and to support the 
apoptosis of epithelial cancer cells by enhancing p53 activity via MDM2 turnover [96]. 
The involvement of miR-145 in an integrated transcriptional regulatory circuit together with 
TFs and chromatin-modifying activities that support the growth and function of breast cancer stem-
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like cells (CSCs) recently emerged [97]. Accordingly, previous results evidenced that expression of 
miR-145 is low in self-renewing human embryonic stem cells (hESCs) but highly up-regulated 
during differentiation. Increased miR-145 expression inhibits hESC self-renewal, represses 
expression of pluripotency genes, such as OCT4, SOX2, and KLF4, and induces lineage-restricted 
differentiation [98]. 
In malignant pleural mesothelioma (MPM) cells miR-145 has the potential to modulate 
many pro-tumorigenic features, including growth, clonogenicity and tumor engraftment in vivo. 
Interestingly, miR-145 targets directly OCT4 and, indirectly, its EMT-promoting target ZEB1, in 
MPM cells. Of note, the levels of miR-145 and OCT4 are inversely correlated in vivo. Promoter 
hyper-methylation may contribute to the low levels of miR-145 in both MPM cells and malignant 
MPM tissues. Importantly, miR-145 down-regulation has been proposed to classify benign versus 
malignant mesothelial tissues [99]. 
In pancreatic cancer cells, the activation of the KRAS signaling pathway consistently leads 
to the repression of the miR-143/miR-145 cluster and this is necessary to maintain the tumorigenic 
potential of these cancer cells. The down-regulation of miR-143/miR-145 expression requires the 
RAS-responsive element-binding protein (RREB1), which represses the miR-143/miR-145 
promoter. Both KRAS and RREB1 transcripts are direct targets of these miRNAs (see Table 4), 
demonstrating the existence of a feed-forward pathway that potentiates KRAS-mediated 
tumorigenesis [100].  
More recently, the RREB1 protein was found to be overexpressed also in colorectal 
adenocarcinoma tumors and cell lines, where the expression of the miR-143/miR-145 primary 
transcript is inversely related to that of RREB1. RREB1 negatively regulates expression of the miR-
143/miR-145 cluster in a KRAS-dependent manner, thus establishing a complex network of 
regulation through which the miR-143/miR-145 cluster is able to modulate KRAS signaling [101]. 
In line with this, additional direct and indirect miR-143/miR-145 target genes have been reported, 
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and they belong to the growth factor receptor-mitogen-activated protein kinase network, as well as 
to the p53 signaling pathway, further supporting a contribution of miR-143/miR-145 to the cell 
signaling pathways involved in colorectal tumorigenesis [102]. 
In prostate cancer miR-145 is consistently down-regulated. A significant inverse correlation 
between the expression of miR-145 and that of the BNIP3 protein was observed in prostate cancer 
and in benign prostate tissues. Accordingly, the overexpression of miR-145 in prostate cancer PC-3 
and DU145 cells significantly down-regulated BNIP3, reduced cell growth, and increased cell 
death. As aforementioned for breast and colon cancer, the overexpression of wild-type p53 resulted 
in the up-regulation of miR-145 expression also in PC-3 cells, with consequent pro-apoptotic 
effects [103]. Wild-type p53 induces up-regulation of miR-145 expression and the inhibitory effects 
of wild-type p53 on migration, invasion, EMT and stemness of PC-3 cells were reversed by anti-
miR-145. These results suggest that loss of wild-type p53 may promote bone metastasis of prostate 
cancer, at least partially through miR-145 down-regulation, and resulting in increased EMT and 
stemness of cancer cells [104]. Moreover, the ectopic expression of miR-145 in LNCaP and DU145 
cell lines led to a reduction in the expression of the ERG protein, suggesting that down-regulation 
of miR-145 associated with prostate cancer may contribute to the increased expression of several 
ERG isoforms that are observed in this tumor type [105].  
In conclusion, several lines of evidence indicate that miR-145 may be largely considered a 
miRNA with tumor suppressor activity, which is involved in the regulation of tumor growth, cell 
invasion and metastasis by targeting multiple cancer related genes, thus offering miR-145 as a novel 
therapeutic target for cancer therapy. 
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MicroRNA-204: a key player in development and tumor suppression 
MicroRNA-204 is encoded by the cancer associated genomic region (CAGR) 9q21.1-q22.3 locus 
that exhibits high frequency of loss of heterozygosity in diverse human cancers [106]. MicroRNA-
204 is an intragenic microRNA, which is located within the transient receptor potential melastatin-3 
(TRPM3) gene belonging to the family of transient receptor potential (TRP) channels [107]. 
MicroRNA-204 activity is highly involved in vertebrate lens development and its loss is 
evidenced in different human cancers (fig. 4). Banfi’s group has shown that microRNA-204 is 
highly expressed in retinal pigment epithelium, lens, ciliary body and neural retina [108]. Its 
activity is required for the proper development of lens and optic cups [108]. The TF Meis2 is a main 
target of the developmental activity of microRNA-204. Aberrant expression of Meis2 released by 
microRNA-204 down-regulation leads to lens abnormalities, microphthalamia, and eye coloboma 
[108]. Interestingly, microRNA-204 and its host gene TRMP3 are transcriptionally co-regulated by 
the developmental TF PAX6 [109]. The analysis of genes aberrantly expressed in PAX6 mutants 
during eye development revealed that microRNA-204 target genes are highly represented. This led 
to identification of novel developmental target genes of microRNA-204, such as Sox11, a member 
of the SoxC family of neuronal TFs, which play a critical role in normal eye development. 
Intriguingly, PAX6 exerts its transcriptional program either modulating directly the expression of 
its targets genes, or indirectly modulating the expression of microRNA-204 that controls that of 
mRNA targets. This gives rise to a complex regulatory network that tunes and integrates coding and 
non-coding gene expression to pursue proper development. 
Growing evidence indicates that microRNA-204 down-regulation is a common alteration in 
different types of human tumors. MicroRNA expression profiling of three different subsets of 
gastric cancer patients revealed that microRNA-204 expression was down-regulated in tumoral 
specimens when compared to matched peritumoral tissues [110]. TRPM3 gene loss was evidenced 
in a large fraction of the analysed gastric patients. This might consequently be one of the molecular 
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mechanisms underlying microRNA-204 down-regulation in human cancers [110-112]. Notably, 
gastric cancer patients can be grouped according to the extent of microRNA-204 down-regulation. 
Those characterized by a severe reduction (more than 0.5-fold) had the worst survival when 
compared to those with a mild downregulation of microRNA-204 (less than 0.5-fold) [110]. The 
pivotal anti-apoptotic protein, BCL-2, was shown to be a target of microRNA-204. Reduced 
expression of microRNA-204 paired with increased staining of BCL-2 in gastric cancer patients 
[110]. BCL-2 ectopic expression counteracted the pro-apoptotic role of microRNA-204 in response 
to 5-Fluorouracil [110]. Down-regulation of microRNA-204 in gastric cancers was also associated 
with increased expression of the class III histone deacetylase SIRT1. The targeting of SIRT1 by 
microRNA-204 ectopic expression favoured mesenchymal to epithelial transition (MET) 
phenotypes and suppressed anoikis resistance of gastric cancer cells [113]. Notably, network 
modelling performed in head and neck tumors by the combination of gene expression data with 
inheritable cancer traits and risk factor loci uncovered 18 targets of microRNA-204 that are mainly 
involved in the development of metastasis [114]. Interestingly, ectopic expression of microRNA-
204 reduced the levels of its target genes and resulted in the inhibition of metastatic phenotype of 
head and neck cancer cell lines [114]. Altogether the localization of microRNA-204 lin the 9q21.1-
q22.3 CAGR locus, a very well known risk factor locus for head and neck tumors and the identified 
target genes account for a bona-fide tumor suppressor micro-RNA. Down-regulation of microRNA-
204-5p was also evidenced in endometrial carcinomas (EC), when compared to normal 
endometrium [115]. This might result from the aberrant expression of the neurotrophic receptor 
tyrosine kinase B (TrkB), which is a target of microRNA-204 [115]. Ectopic expression of TrkB led 
to accumulation of phospho-STAT3 that was recruited at a specific binding site of microRNA-204 
host gene, TRMP3, and might account for microRNA-204 down-regulation in EC [115]. Loss of 
microRNA-204 expression through promoter methylation was evidenced in both glioma and neural 
stem cells [116]. This led to enhanced migration of glioma cells and to the acquisition of a stem 
cell-like phenotype. Indeed, attenuation of promoter methylation increased microRNA-204 
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expression in glioma cells and ectopic expression of microRNA-204 suppressed the tumorigenic 
potential of glioma cells. Mechanistic investigation revealed that microRNA-204 targets the 
expression of SOX4, a stemness TF, and EphB2, a receptor that promotes migration [116].  
MicroRNA-204 is a transcriptional target of the von Hippel-Lindau tumor suppressor gene 
(VHL) that is lost in the largest fraction of clear cell renal cell carcinomas (ccRCC) [117]. VHL-
induced expression of microRNA-204 resulted in the increased expression of short transcripts of 
TRMP3, thus indicating that microRNA-204 is not, at least in ccRCC, transcriptionally co-regulated 
with the large transcript encoding the full-length TRMP3 protein [117]. MicroRNA-204 expression 
is clearly reduced in ccRCC with known VHL status when compared to matched normal kidney 
samples and its reconstitution led to growth inhibition in vitro and in vivo [117]. The transcriptional 
tumor suppressor axis VHL/microRNA-204 inhibited macroautophagy. This occurs through the 
ability of microRNA-204 to directly target LC3B and VHL-induced expression of the parolog, 
LC3C that caused growth suppression. 
It appears increasingly clear that both in development and in cancer the down-regulation of 
microRNA-204 disables coordinated transcriptional network and instigates unscheduled signalling 
pathways. These might contribute to developmental diseases or to aberrant proliferation, metastasis 
and poor response to conventional anticancer treatments. The identification of additional 
microRNA-204 targets and the dissection of the epigenetic events regulating its expression in 
normal and malignant tissues might provide intriguing insights, which would make microRNA-204 
an appealing and hopefully druggable target. 
 
Perspectives and open questions 
Collectively, the reviewed groups of tumor suppressor microRNAs are emerging as major players 
of the cellular response to different types of oncogenic insults. Together with coding RNAs, 
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epigenetic modifications and other mechanisms, this response can lead to clonal expansion, 
spreading and chemoresistance of a given tumor. Along with ever improving understanding of the 
concerted alterations in microRNAs, many cardinal questions remain open. For example, it is 
logical that tumor suppressor microRNAs maintain complex crosstalks with coding tumor 
suppressor RNAs in order to fortify barriers to oncogenicity, but the details of this interplay are 
currently unknown. Also unknown are the molecular determinants underlying activation of 
intragenic and intergenic tumor suppressor microRNAs upon oncogenic insults. The multiplicity of 
RNA targets of each tumor suppressor microRNA poses a pivotal challenge. Moreover, it is 
conceivable that the tumor cell context influences target specificity, and consequently determines 
biological effects. These and additional issues will require deeper, perhaps more integrated 
understanding of tumor suppressor microRNAs.  
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Legends to figures 
Figure 1. Biogenesis and targets of microRNAs encoded by the miR-10b locus. RNA polymerase II 
transcribes miRNA genes, generating long primary transcripts (pri miRNAs). Drosha-mediated 
cleavage of pri-miRNAs leads to the formation of a hairpin molecule, the pre-microRNA, that is 
exported to the cytoplasm by the exportin-5/RAN-GTP complex.  In the cytoplasm, the pre-miRNA 
is cleaved by Dicer, to produce a ~22-nt RNA duplex. In the case of the mir-10b locus, these 
comprise two distinct 5’ phosphorylated strands with 3′ overhangs, miR-10b-5p and miR-10b-3p. 
The functional strand of the duplex is incorporated into a multi-protein complex, the RNA-induced 
silencing complex (RISC), which regulates protein expression. In particular, in breast cancer 
functional miR-10b-3p targets BUB1, PLK1 and CCNA2 mRNAs, inducing a decrease in protein 
expression and a consequent inhibition of cancer cell proliferation. 
Figure 2. Let-7c regulation and functions. The biogenesis of the let-7 family, including let-7c, is 
controlled by the RNA-binding proteins Lin28 and Lin28B. In particular, Lin28B inhibits Drosha-
mediated formation of pre-let-7, as well as Dicer-mediated formation of let-7 duplexes. In turn let-7 
family members downregulate expression of Lin28 and Lin28B, thereby establishing  a negative 
feedback loop. Let-7c is downregulated in many types of tumors and its overexpression has a 
negative effect on cancer cells proliferation, metastasis and epithelial to mesenchymal transition. 
Figure 3. Macrophage-mediated miR-223 transfer. (A) miR-223 is released by macrophages into 
microvesicles and it induces cellular differentiation of naive monocytes to increase in immune 
functions. (B) Macrophages mediate miR-223 transfer to cancer cells by mean of cell contact and 
gap junction communication. The transferred miR-223 is functionally active, and through decreased 
expression of Stathmin-1 (STMN1) and insulin-like growth factor-1 receptor (IGF-1R ), it induces 
growth arrest of cancer cells. 
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Figure 4. miR-204 functions. miR- 204 plays important roles in both eye development (A) and in 
tumor suppression (B). During eye development, high levels of miR-204 induce a reduction in 
Meis2 and Sox11 protein expression, thereby modulating the expression of other target proteins that 
contribute to normal development of the lens and retina. In particular, miR-204 expression is 
positively regulated by Pax6, a regulator of multiple processes during eye development, that in turn 
is activated by Meis2. Hence, miR-204 and Pax6 co-regulate each other via a negative feedback 
loop. miR-204 is downregulated in different types of cancer. Its tumor suppressor activity is 
mediated by the modulation of the expression of different oncoproteins depending on the cellular 
context.  
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